MARC, a Novel Modular Chimeric Antigen Receptor, Improves T Cell-Based Cancer Immunotherapies by Preventing Early T Cell Exhaustion, and Enhancing Persistence

Investigators developed a modular chimeric antigen receptor leveraging the same assembly principles found in native activating immune receptors to reestablish the intrinsic safeguards in receptor expression and signaling.